Topics
Glioblastoma | Treatment | Targeted therapy | Angiogenesis inhibitors | Observational studies
Home > Publications > Topics > Glioblastoma > Treatment > Targeted therapy > Angiogenesis inhibitors > Observational studies
Nimotuzumab
Wu Y, Chen Z, Shi M, Qiu S, Zhang Y.
Nimotuzumab
and bevacizumab combined with temozolomide and radiotherapy in
patients with newly diagnosed glioblastoma multiforme: a
retrospective single-arm study.
J
Neurooncol. 2025 Jan 6. doi:
10.1007/s11060-024-04932-8. PMID:
39760795. Observational study˰
ˍ
does dose matter?
Cerretti G, Bosio A, Librizzi G, Pintacuda G, Caccese M,
Salvalaggio A, Zoccarato M, Parisi A, Padovan M, Maccari M,
Cavallin F, Bellu L, Pasqualetti F, Ius T, Denaro L, Volpin F,
Coppola M, Lonardi S, Lombardi G.
Bevacizumab
in recurrent glioblastoma: does dose matter? Our monocentric and
comparative experience.
J
Neurooncol. 2025 Mar 10. doi:
10.1007/s11060-025-04992-4. PMID:
40063186. Observational study.
ˍ